A Phase 2b Open-label Extension Study to Evaluate the Long-term Safety and Efficacy of NEOD001 in Subjects with Light Chain (AL) Amyloidosis who were previously enrolled in Study NEOD001-201 (Pronto) previously enrolled in Study NEOD001-201 (PRONTO)

Administered By

Awarded By

Contributors

Start/End

  • October 13, 2017 - June 22, 2018